GET DAILY SIGNALSAmylyx Pharmaceuticals (AMLX) +66% Climb on Avexitide Trial Success
Key Takeaways
- AMLX shares climbed roughly 66% over the last 30 days, rising from $20.31 to $33.75, driven by positive late-stage clinical data for its lead drug candidate, avexitide.
- On August 18, 2026, Amylyx reported that avexitide met its primary endpoint in the Phase 3 LUCIDITY trial, cutting severe hypoglycemic events by 55% versus placebo in post-bariatric hypoglycemia (PBH).
- Several analysts raised price targets following the data, including Guggenheim and H.C. Wainwright at $55, while the company priced an upsized $500 million stock offering.
- The stock is up roughly 140% over the last three months, extending a climb from about $14 in early June.
- Investors are now focused on the company's planned FDA New Drug Application (NDA) for avexitide, expected by the end of 2026.
Company Background and Pipeline Focus
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, developing treatments for neurodegenerative and endocrine conditions. Its lead candidate, avexitide, is a first-in-class GLP-1 receptor antagonist aimed at post-bariatric hypoglycemia, a rare disorder involving sharp drops in blood sugar following weight-loss surgery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The rest of the pipeline features AMX0035 for Wolfram syndrome, AMX0114 targeting calpain-2 in ALS, and AMX0318. The company gained U.S. approval for Relyvrio in ALS in 2022 but withdrew it in 2024 after the Phase 3 PHOENIX trial missed its goal. With no products on the market today, progress with avexitide remains central to the investment case.
Stock Performance: 30-Day Move and Quarterly Trend
Over the past 30 days, AMLX advanced from a July 31 close of $20.31 to $33.75 on August 31, 2026, for a gain of about 66%. The bulk of the advance came on August 18 when the shares jumped roughly 63% in one session to $35.11 after the LUCIDITY readout, touching a 52-week high. Prices later reached an intraday peak near $41.13 on August 21 before easing to $33.75 by month-end.
The three-month picture shows even stronger gains. AMLX has more than doubled since early June when it traded near $14, posting a rise of roughly 140%. That longer move reflects steady buying ahead of the data, followed by the sharp re-rating once results were released.
Primary Catalyst in the Recent Advance
The key driver was the August 18 release of positive topline results from the Phase 3 LUCIDITY trial of avexitide in PBH. The drug met its FDA-agreed primary endpoint by lowering the composite rate of Level 2 and Level 3 hypoglycemic events 55% versus placebo and cleared all secondary endpoints with a favorable safety profile. No approved treatments exist for PBH, and avexitide already carries FDA Breakthrough Therapy and Orphan Drug status. From what I see, this outcome shifted sentiment quickly.
Analyst reactions followed promptly. Guggenheim lifted its target from $40 to $55, H.C. Wainwright moved from $34 to $55, Robert W. Baird raised its price target from $28 to $52, and Stifel increased its target from $21 to $45, with Wolfe Research upgrading to Strong Buy. Amylyx also launched a $350 million offering that was upsized and priced at $500 million, reflecting solid demand, and finished enrollment in the Phase 1 LUMINA trial of AMX0114.
Quarterly Build-Up and Earnings Context
The broader quarterly advance stemmed from growing anticipation ahead of the LUCIDITY readout. The stock moved in a $13–$24 range through June and July as investors positioned for the pivotal data. Second-quarter results released on August 6 showed a net loss of $43.42 million, or $0.39 per share, a bit wider than expected, yet attention stayed on the clinical catalyst rather than near-term finances. This is important because the August 18 data validated the lead asset and redirected focus toward regulatory filing and eventual commercialization.
The $500 million financing is earmarked for pre-commercial work and manufacturing scale-up, supporting a potential 2027 launch if approval is granted.
Upcoming Milestones and Risks to Monitor
The next significant step is the planned NDA submission for avexitide in PBH by year-end 2026, followed by FDA review and a possible commercial launch. Additional LUCIDITY data presentations at medical conferences, updates on manufacturing readiness, and pipeline progress with AMX0035 in Wolfram syndrome and AMX0114 in ALS will also draw attention. Key risks include regulatory uncertainty, execution in a competitive setting, and dilution from the recent equity raise. As a clinical-stage firm without current revenue, Amylyx continues to hinge on clinical and regulatory outcomes.
Exploring AI-Assisted Research Tools
In my own work I occasionally turn to Tickeron’s AI Trading Bots for additional perspective on how clinical events translate into trading patterns. The platform offers a range of automated strategies across different timeframes and risk profiles, which can complement fundamental analysis when evaluating names like this one. It has helped me compare historical reactions across similar biotech catalysts without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
AMLX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AMLX turned positive on October 20, 2026. Looking at past instances where AMLX's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMLX's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AMLX as a result. In 67 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
AMLX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in 233 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 189 of 218 cases where AMLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AMLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.481) is normal, around the industry mean (6.379). P/E Ratio (-20.922) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement